2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

HISTOLOGIC FEATURES AND MANAGEMENT OF LOW- AND HIGH-GRADE UTERINE SARCOMAS
48. Lee CH, Ou WB, Mariño-Enriquez A, et al. 14-3-3 fusion oncogenes in
high-grade endometrial stromal sarcoma. Proc Natl Acad SciUSA. 2012 Jan
5. [Epub ahead of print]
49. Nordal RR, Kristensen GB, Kaern J, et al. The prognostic significance
of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy
in endometrial stromal sarcoma. Gynecol Oncol. 1996;62:254-259.
50. Gadducci A, Sartori E, Landoni F, et al. Endometrial stromal sarcoma:
analysis of treatment failures and survival. Gynecol Oncol. 1996;63:247-253.
51. Berchuck A, Rubin SC, Hoskins WJ, et al. Treatment of endometrial
stromal tumors. Gynecol Onco. 1990;36:60-65.
52. Piver MS, Rutledge FN, Copeland L, et al. Uterine endolymphastic
stromal myosis: A collaborative study. Obstet Gynecol 1995;64:173.
53. Sutton G, Blessing JA, Park R, et al. Ifosfamide treatment of recurrent
or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy:
a study of the Gynecologic Oncology Group. Obstet Gynecol. 1996;
87:747-750.
54. Yamawaki T, Shimizu Y, Hasumi K. Treatment of stage IV “highgrade”
endometrial stromal sarcoma with ifosfamide, adriamycin, and cisplatin.
Gynecol Oncol. 1997;64:265-269.
55. Krivak TC, Seidman JD, McBroom JW, et al. Uterine adenosarcoma
with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of
treatment and survival. Gynecol Oncol. 2001;83:89-94.
56. Acharya S, Hensley ML, Montag AC, et al. Rare Uterine Cancers.
Lancet Oncology. 2005;6:961-971.
361